CNS Drugs

, Volume 4, Issue 6, pp 422–431 | Cite as


Options in Pharmacotherapy
  • David Baldwin
  • Shauna Rudge
  • Sally Thomas
Practical Therapeutics Treatment of Dysthymia



Dysthymic disorder (dysthymia) was introduced into the group of affective or mood disorders with the publication of the DSM-III in 1980, Although little was known of dysthymia at the time of its inclusion in this manual, subsequent research has resulted in a more detailed description of the phenomenology, epidemiology and associated comorbidity of the disorder

Accurate diagnosis of dysthymia remains difficult, being dependent on the recall of symptoms by patients. States of chronic mild depression, such as dysthymia, appear to be rather common, with a point prevalence of around 2 to 4%. Comorbidity with other psychiatric disorders is common, leading certain authorities to dispute the existence of ‘pure’ dysthymia.

Although chronic mild depression is associated with considerable use of health service resources, and prescriptions of psychotropic drugs are common, the drug treatment of dysthymia has not been investigated extensively. Furthermore, methodological flaws characterise many of the existing published studies of treatments for the disorder.

Nevertheless, recent research supports the use of antidepressant medication in certain groups of patients. Imipramine, certain selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors and moclobemide may be of benefit, particularly in patients with ‘double depression’, in whom major depressive episodes complicate an underlying dysthymic disorder.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980Google Scholar
  2. 2.
    Akiskal HS. Towards a definition of dysthymia: boundaries with personality and mood disorders. In: Burton SW, Akiskal HS, editors. Dysthymic disorder. London: Gaskell, 1990: 1–12Google Scholar
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2nd ed. Washington, DC: American Psychiatric Association, 1968Google Scholar
  4. 4.
    Weissman MM, Leaf PJ, Bruce ML, et al. The epidemiology of dysthymia in five communities: rates, risks, co-morbidity, and treatment. Am J Psychiatry 1988; 145: 815–9PubMedGoogle Scholar
  5. 5.
    Markowitz JC, Moran ME, Kocsis JH, et al. Prevalence and co-morbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord 1992; 24: 63–71PubMedCrossRefGoogle Scholar
  6. 6.
    Wells KB, Stewart A, Hays RD, et al. The functioning and wellbeing of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914–9PubMedCrossRefGoogle Scholar
  7. 7.
    Frances A, Hall W. Work in progress on the DSM-IV mood disorders. In: Feighner JP, Boyer WF, editors. Diagnosis of depression. Perspectives in psychiatry. Vol. 2. Chichester: John Wiley & Sons, 1991Google Scholar
  8. 8.
    Angst J, Wicki W. The Zurich Study. XI. Is dysthymia a separate form of depression? Results of the Zurich cohort study. Eur Arch Psychiatry Clin Neurosci 1991; 240: 349–54PubMedCrossRefGoogle Scholar
  9. 9.
    Howland RH. Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 1991; 11: 83–92PubMedCrossRefGoogle Scholar
  10. 10.
    WPA Dysthymia Working Group. Dysthymia in clinical practice. Br J Psychiatry 1995; 166: 174–88CrossRefGoogle Scholar
  11. 11.
    World Health Organization. The ICD-IO classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992Google Scholar
  12. 12.
    Montgomery SA. Recurrent brief depression. In: Montgomery SA, Com TH, editors. Psychopharmacology of depression. Oxford: Oxford Medical Publications, 1994: 129–40Google Scholar
  13. 13.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  14. 14.
    Kocsis JH, Frances AJ. A critical discussion of DSM-III dysthymic disorder. Am J Psychiatry 1987; 144: 1534–42PubMedGoogle Scholar
  15. 15.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987Google Scholar
  16. 16.
    Faravelli C, Incerpi G. Epidemiology of affective disorders in Florence: preliminary results. Acta Psychiatr Scand 1985; 72: 331–3PubMedCrossRefGoogle Scholar
  17. 17.
    Kashani J, Carlson GA, Beck NC, et al. Depression, depressive symptoms and depressed mood among a community sample of adolescents. Am J Psychiatry 1987; 144: 931–4PubMedGoogle Scholar
  18. 18.
    Wittchen HU, von Zerssen D. Veäufe behandelter und unbehandelter Depressionen and Angststörungen: eine klinischpsychiatrische und epidemiologische Verlaufsuntersuchung. Berlin: Springer, 1987Google Scholar
  19. 19.
    Bland RC, Newman Sc. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand 1988; 77: 24–32CrossRefGoogle Scholar
  20. 20.
    Kivelae SL, Pahkala K, Laippala P. Prevalence of depression in an elderly population in Finland. Acta Psychiatr Scand 1988; 78: 401–13CrossRefGoogle Scholar
  21. 21.
    Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58PubMedCrossRefGoogle Scholar
  22. 22.
    Klerman GL, Weissman MM, Frank E, et al. Evaluating drug treatments of depressive disorders. In: Prien RF, Robinson DS. editors. Clinical evaluation of psychotropic drugs. Principles and guidelines. New York: Raven Press, 1994: 281–325Google Scholar
  23. 23.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–65PubMedCrossRefGoogle Scholar
  24. 24.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRefGoogle Scholar
  25. 25.
    Mason BJ, Kocsis JH, Frances AJ. The Cornell Dysthymia Rating scale. New research abstract no. 231. Presented at the 142nd Annual Meeting of the American Psychiatric Association; 1989 May: San Francisco (CA)Google Scholar
  26. 26.
    Guy W, Ban TA, Schaffer JD. Differential treatment responsiveness among mildly depressed patients. In: Clayton PJ, Barrett JE, editors. Treatment of depression: old controversies and new approaches. New York: Raven Press. 1983: 229–36Google Scholar
  27. 27.
    Stewart JW, Quitkin FM, Liebowitz MR, et al. Efficacy of desipramine in depressed outpatients: response according to research diagnostic criteria diagnoses and severity of illness. Arch Gen Psychiatry 1983; 40: 202–7PubMedCrossRefGoogle Scholar
  28. 28.
    Stewart JW, McGrath PJ, Liebowitz MR, et al. Treatment outcome validation of DSM-III depressive sub-types: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42: 148–53CrossRefGoogle Scholar
  29. 29.
    Harrison W, Rabkin J, Stewart JW, et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986; 47: 346–9PubMedGoogle Scholar
  30. 30.
    Davidson JRT, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression. And its relationship to depressive nosology. Arch Gen Psychiatry 1988; 45: 120–7PubMedCrossRefGoogle Scholar
  31. 31.
    Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253–7PubMedCrossRefGoogle Scholar
  32. 32.
    Paykel ES, Hollyman JA, Freeling P, et al. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo controlled trial. J Affect Disord 1988; 14: 83–95PubMedCrossRefGoogle Scholar
  33. 33.
    Tyrer P, Murphy S, Kingdon D, et al. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 1988; 11: 235–40CrossRefGoogle Scholar
  34. 34.
    Costa-e-Silva JA. Treatment of dysthymic disorder with lowdose amisulpride. A comparative study of 50 mg/day amisulpride versus placebo. Ann Psychiatry 1990; 5: 242–9Google Scholar
  35. 35.
    Bersani G, Pozzi F, Marini S, et al. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83: 244–8PubMedCrossRefGoogle Scholar
  36. 36.
    Hellerstein DJ, Yanavitch D, Rosenthal J, et al. A randomised double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150: 1169–75PubMedGoogle Scholar
  37. 37.
    Stabl M. Pharmacotherapy of dysthymia. A controlled study with moclobemide. imipramine and placebo. Proceedings of the American Psychiatric Association; 1993 May: San Francisco (CA)Google Scholar
  38. 38.
    Kocsis JH, Thase ME, Koran L, et al. Pharmacotherapy for pure dysthymia: sertraline versus imipramine and placebo. Eur Neuropsychopharmacology 1994; 4 (3 Suppl.): S204CrossRefGoogle Scholar
  39. 39.
    Bakish D, Lapierre YD, Weinstein C, et al. Ritanserin. Imipramine and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1995; 13: 409–14Google Scholar
  40. 40.
    Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35: 773–82PubMedCrossRefGoogle Scholar
  41. 41.
    Baldwin DS, Rudge SE. The tolerability of mocJobemide. Rev Contemp Pharmacother 1994; 5: 57–65Google Scholar
  42. 42.
    Ravindran AV, Biasik RJ, Lapierre YD. Therapeutic efficacy of serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 1993; 39: 21–6Google Scholar
  43. 43.
    Fluxe K, Ogren SO, Agnati LF, et al. Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 1983; 22: 1203–9CrossRefGoogle Scholar
  44. 44.
    Reyntjens A, Gelden YG, Hopperbrouwers HJA, et al. Thymosthenic effects of ritanserin (R 5667), a centrally acting serotonin S-2 receptor blocker. Drug Dev Res 1986; 8: 205–11CrossRefGoogle Scholar
  45. 45.
    Bech P, Mellergard M, Ottoson JO. Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment. Acta Psychiatr Scand 1991; 365 Suppl.: 39–45Google Scholar
  46. 46.
    Cummins JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443–54Google Scholar
  47. 47.
    Markovitz Je. Psychotherapy of the post dysthymic patient. J Psychother Prac Res 1993; 2: 157–63Google Scholar
  48. 48.
    Waring EM, Chamberlaine CH, McCrank EW, et al. Dysthymia: a randomised study of cognitive marital therapy and antidepressants. Can J Psychiatry 1988; 33: 96–9PubMedGoogle Scholar
  49. 49.
    McCullough JP. Psychotherapy for dysthymia. A naturalistic study of ten patients. J Nerv Ment Dis 1991; 179: 734–40PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • David Baldwin
    • 1
  • Shauna Rudge
    • 2
  • Sally Thomas
    • 1
  1. 1.University Department of Psychiatry, Faculty of MedicineUniversity of SouthamptonHampshireEngland
  2. 2.Department of PsychiatryCharing Cross HospitalLondonEngland

Personalised recommendations